Smart Inhalers Market Size, Share & Industry Analysis, By Product (Dry Powder Inhaler (DPI) -Based Inhalers and Metered Dose Inhaler (MDI) -Based Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel) and Regional Forecast, 2020-2027 (Includes COVID-19 Business Impact)

  • TBI512672
  • September 24, 2020
  • Global
  • 132 pages
  • ROIF Expert

We have updated Smart Inhalers Market with respect to COVID-19 Business Impact. Inquire before buying This report focuses on the Smart Inhalers market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Smart Inhalers market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Smart Inhalers Market: Segment Analysis

The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Smart Inhalers Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Smart Inhalers Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.

List of Companies Profiled

Core Focus on Research and Development Activities by Adherium and Propeller Health to Strengthen Their Market Position The global market is at its nascent stage of development. Also, a great number of companies operate actively here. Cohero Health Inc. and Adherium, Propeller Health, are anticipated to lead the market. Certain factors, such as emphasis on research & development activities, ownership of technology, and robust focus on the consolidation of distribution channels can be attributed for the players to hold prominent smart inhaler market share. Also, players such as AstraZeneca plc, GlaxoSmithKline, Novartis AG, and others are vigorously contributing in the smart inhalers segment owing to their strong brand presence and well-established marketing channels.


  • Adherium
  • Propeller Health
  • Cohero Health Inc.
  • GlaxoSmithKline
  • AstraZeneca plc
  • Novartis AG
  • 3M Company
  • Teva Pharmaceuticals
  • Vectura Group
  • Others


In September 2020,

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. The FDA-approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg. There is an additional strength for asthma alone which is fluticasone furoate / umeclidinium / vilanterol 200/62.5/25mcg. The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US. The approval is an important advance for patients as it allows them to benefit from triple therapy by using one inhaler, once-a-day. Trelegy’s approval for the maintenance treatment of asthma in patients aged 18 years and older introduces a new paradigm for managing the approximately 30% of adult asthma patients who still experience symptoms despite being adherent to inhaled corticosteroids/ long-acting beta-agonist (ICS/LABA) combination therapy. In the US there are almost 20 million adults living with asthma and many of those continue to live with and adapt their lives around ongoing symptoms. FF/UMEC/VI is a combination of three molecules in a single inhaler that only needs to be taken in a single inhalation, once a day. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler.

November 2019

-Lupin announced the launch of ADHERO, a novel connected smart device for metered-dose inhalers. Such novel product launch enabled the company to generate more revenue in the global market and thereby augmenting the market growth of smart inhalers.

January 2016

“Qualcomm Life and Novartis announced the strategic agreement on the development of NovartisBreezhaler inhaler, a digital inhaler for patients suffering from COPD. Such inorganic strategic agreements assisted both companies to hold a strong position in the smart inhalers market.


The report offers comprehensive data regarding various insights of the market. Some of them are competitive landscape, growth drivers, regional analysis, restraints, and other related aspects. It further offers analytical insights of the digital inhalers estimations and market trends to exemplify the forthcoming investment outcomes. The data gathered from several sources are quantitatively evaluated from 2020 to 2027 to provide the financial competency of the market. The data gathered in the report has been collected from various secondary and primary sources.

Report Scope & Segmentation


By Product

  • Dry Powder Inhaler (DPI)- based Inhalers
  • Metered Dose Inhaler (MDI)- based Inhalers

By Disease indication

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channel

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, and Rest of Asia- Pacific)
  • Rest of the world (Row)

Table of Content
Chapter 1. Methodology and Scope 
1.1. Research Methodology 
1.2. Research Scope & Assumptions 
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Smart Inhalers Market
3.1. Market Segmentation 
3.2. Market Size and Growth Prospects, 2019 - 2029 
3.3. Value Chain Analysis 
3.4. Market Dynamics 
3.4.1. Market driver analysis 
3.4.2. Market restraint analysis
Chapter 4. Market Size by Application
4.1 Smart Inhalers Market Consumption by Application (2015-2020) 
4.2 Smart Inhalers Market Consumption by Application (2020-2029) 

| 

Request a sample

Fill below form to request a sample


Please fill this form to enquire before buying


You can request for discount regarding the report by using below form